A particularly promising one is molnupiravir, for which the US has just signed a multi-million dollar preliminary contract. This antiviral drug is said to block the virus from multiplying in the body. The active ingredient only develops in the body after ingestion. The metabolism creates small building blocks, similar to those of human RNA. They are built into the viral RNA, but have small flaws. If the errors then pile up, the virus can neither multiply nor be transmitted to other people. With molnupiravir, it is crucial that the drug is used early in the course of the disease to slow the virus from multiplying.
In Europe, a total of four active ingredients against Covid-19 are about to be approved. They could be approved as early as the summer. In exceptional cases, they are already recommended by the European Medicines Agency.
I am Pierce Boyd, a driven and ambitious professional working in the news industry. I have been writing for 24 Hours Worlds for over five years, specializing in sports section coverage. During my tenure at the publication, I have built an impressive portfolio of articles that has earned me a reputation as an experienced journalist and content creator.
